Sattva S. Neelapu; Frederick L. Locke; Nancy L. Bartlett; Lazaros J. Lekakis; David B. Miklos; Caron A. Jacobson; Ira Braunschweig; Olalekan O. Oluwole; Tanya Siddiqi; Yi Lin; John M. Timmerman; Patrick J. Stiff; Jonathan W. Friedberg; Ian W. Flinn; André Goy; Brian T. Hill; Mitchell R. Smith; Abhinav Deol; Umar Farooq; Peter A. McSweeney; Javier Muñoz; Irit Avivi; Januario E. Castro; Jason R. Westin; Julio C. Chávez; Armin Ghobadi; Krishna V. Komanduri; Ronald Levy; Eric D. Jacobsen; Thomas E. Witzig; Patrick M. Reagan; Adrian Bot; John M. Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y. Go · 2017 · New England Journal of Medicine
Paper
BACKGROUND: In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy. METHODS: anti-CD19 CAR T cells per kilogram of body weight after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine. The primary end point was the rate of objective response (calculated as the combined rates of complete response and partial response). Secondary end points included overall survival, safety, and biomarker assessments. RESULTS: Among the 111 patients who were enrolled, axi-cel was successfully manufactured for 110 (99%) and administered to 101 (91%). The objective response rate was 82%, and the complete response rate was 54%.With a median follow-up of 15.4 months, 42% of the patients continued to have a response, with 40% continuing to have a complete response. The overall rate of survival at 18 months was 52%. The most common adverse events of grade 3 or higher during treatment were neutropenia (in 78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 13% and 28% of the patients, respectively. Three of the patients died during treatment. Higher CAR T-cell levels in blood were associated with response. CONCLUSIONS: In this multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events. (Funded by Kite Pharma and the Leukemia and Lymphoma Society Therapy Acceleration Program; ZUMA-1 ClinicalTrials.gov number, NCT02348216.).
Analysis
This study evaluates the efficacy and safety of axicabtagene ciloleucel (axi-cel), an anti-CD19 CAR T-cell therapy, in patients with refractory large B-cell lymphoma.
Discovery
Estelle Baulu; Célia Gardet; Nicolas Chuvin; Stéphane Depil
Silvia Arcangeli; Camilla Bove; Claudia Mezzanotte; Barbara Camisa; Laura Falcone; Francesco Manfredi; Eugenia Bezzecchi; Rita El Khoury; Rossana Norata; Francesca Sanvito; Maurilio Ponzoni; Beatrice Greco; Marta Angiola Moresco; Matteo G. Carrabba; Fabio Ciceri; Chiara Bonini; Attilio Bondanza; Monica Casucci
Robert C. Sterner; Rosalie M. Sterner; Rosalie M. Sterner; Rosalie M. Sterner
Matteo Morotti; Ashwag Albukhari; Abdulkhaliq Alsaadi; Mara Artibani; James D. Brenton; Stuart M. Curbishley; Tao Dong; Michael L. Dustin; Zhiyuan Hu; Nicholas McGranahan; Martin L. Miller; Laura Santana-Gonzalez; Leonard W. Seymour; Tingyan Shi; Peter Van Loo; Christopher Yau; Helen White; Nina Wietek; David N. Church; David C. Wedge; Ahmed A. Ahmed
Yongxian Hu; Yali Zhou; Mingming Zhang; Wengang Ge; Yi Li; Li Yang; Guoqing Wei; Lu Han; Hao Wang; Shuhui Yu; Yi Chen; Yanbin Wang; Xiaohong He; Xingwang Zhang; Ming Gao; Jingjing Yang; Xiuju Li; Jiangtao Ren; He Huang
Joe-Marc Chauvin; Hassane M Zarour
Source record